A new research paper was published in Oncotarget titled, "Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers and overcomes cancer stemness, trifluridine-induced ...

Regorafenib showed promise compared to standard of care in the randomised multi-institutional investigator-sponsored Phase 2 trial REGOMA, published in The Lancet Oncology in December, 2018.

Marwan G. Fakih, MD, discusses the next steps for the clinical development of the balstilimab plus botensilimab in ...